Insulet (NASDAQ:PODD) Given New $249.00 Price Target at Canaccord Genuity Group

Insulet (NASDAQ:PODD) had its price target lowered by stock analysts at Canaccord Genuity Group from $435.00 to $249.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. Canaccord Genuity Group’s price target would suggest a potential upside of 58.12% from the company’s previous close.

A number of other brokerages have also issued reports on PODD. Robert W. Baird decreased their target price on Insulet from $360.00 to $248.00 in a research report on Thursday. Jefferies Financial Group reduced their price objective on shares of Insulet from $400.00 to $360.00 in a research report on Thursday. Oppenheimer dropped their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday. TD Cowen cut shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research note on Monday, January 26th. Finally, Citigroup reduced their price target on shares of Insulet from $230.00 to $175.00 in a research report on Thursday. Eighteen analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $263.91.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $6.20 during trading on Thursday, reaching $157.48. 81,593 shares of the company’s stock traded hands, compared to its average volume of 1,069,567. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. Insulet has a fifty-two week low of $148.30 and a fifty-two week high of $354.88. The company has a 50-day simple moving average of $212.92 and a 200-day simple moving average of $264.96. The firm has a market cap of $10.91 billion, a PE ratio of 44.72, a P/E/G ratio of 0.99 and a beta of 1.20.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the firm posted $1.02 EPS. Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts predict that Insulet will post 6.27 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Michael R. Minogue acquired 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently modified their holdings of the business. Swiss National Bank lifted its stake in shares of Insulet by 7.1% in the first quarter. Swiss National Bank now owns 206,500 shares of the medical instruments supplier’s stock worth $43,332,000 after buying an additional 13,600 shares in the last quarter. Angeles Wealth Management LLC raised its holdings in Insulet by 5.3% in the 1st quarter. Angeles Wealth Management LLC now owns 2,725 shares of the medical instruments supplier’s stock valued at $572,000 after acquiring an additional 136 shares during the last quarter. C WorldWide Group Holding A S increased its holdings in shares of Insulet by 17.7% in the first quarter. C WorldWide Group Holding A S now owns 99,908 shares of the medical instruments supplier’s stock valued at $20,965,000 after purchasing an additional 15,000 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. lifted its position in Insulet by 38.9% during the first quarter. Financiere des Professionnels Fonds d investissement inc. now owns 2,398 shares of the medical instruments supplier’s stock worth $503,000 after buying an additional 671 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in Insulet by 12.3% during the first quarter. Bessemer Group Inc. now owns 4,024 shares of the medical instruments supplier’s stock worth $845,000 after buying an additional 442 shares in the last quarter.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.42 vs. ~$1.19 consensus and revenue $761.7M (+33.9% Y/Y), driven by strong Omnipod demand. This confirms solid top-line momentum. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Company raised its annual revenue growth outlook after the quarter, citing sustained demand for its tubeless insulin pumps — a supportive signal for medium-term sales trajectory. Insulet lifts annual revenue forecast after quarterly beat
• Neutral Sentiment: Earnings call commentary was broadly upbeat (Omnipod growth emphasized) and management provided slide materials/transcripts for investors to parse execution details. These materials clarify drivers but don’t change the headline beat. Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY 2026 EPS guidance appears below some Street estimates (company set FY EPS around ~6.21 vs. ~6.33 consensus cited by analysts), which likely disappointed investors despite the revenue upgrade. Earnings and guidance details
• Negative Sentiment: BTIG cut its price target from $320 to $260 (still a Buy rating); the PT reduction signals some analyst re?valuation and may have amplified selling pressure. BTIG price target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.